Janus Kinase 1 in Vitiligo & Psoriasis

Not Applicable

Completed

• Conditions: Vitiligo
• Interventions: Other: skin biopsy

• Registration Number: NCT03762551
• Lead Sponsor: Cairo University

Brief Summary

Assessment of the level of JAK1 in both vitiligo and psoriasis patients before and after treatment with NB-UVB which is considered a gold standard therapy for both diseases.

Detailed Description

Not available

Study Timeline

• Status Verified: 2015-11
• Study Start: 2015-12
• Primary Completion: 2016-11
• Study Completion: 2016-11
• Study First Submitted: 2018-11-30
• Study First Submitted QC: 2018-11-30
• Last Update Submitted: 2018-11-30
• Study First Posted: 2018-12-03
• Last Update Posted: 2018-12-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• age above 12 years of age.
• psoriasis vulgaris or non-segmental vitiligo
• patients who received no systemic or topical treatment at least 6 weeks prior to enrollment into the study.

Exclusion Criteria

• psoriasis patients with erythrodermic psoriasis, pustular psoriasis or associated psoriatic arthritis
• vitiligo patients with segmental or universal vitiligo were excluded from the study.
• any patient with a photosensitive disorder or any contraindication to phototherapy exposure, e.g., history or presence of malignant or premalignant skin lesions.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
vitiligo	skin biopsy	assess the level of JAK1 in vitiligo patients before and after treatment with NB-UVB
psoriasis	skin biopsy	assess the level of JAK1 in psoriasis patients before and after treatment with NB-UVB
controls	skin biopsy	assess the level of JAK1 in controls

Primary Outcome Measures

Name	Time	Method
Measurement of the tissue level of JAK1 in both vitiligo and psoriasis patients before and after treatment with NB-UVB	1 year